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Abstract
Background:  Unremitting fatigue and unrefreshing sleep, hallmark traits of Chronic Fatigue
Syndrome (CFS), are also pathognomonic of sleep disorders. Yet, no reproducible perturbations
of sleep architecture, multiple sleep latency times or Epworth Sleepiness Scores are found to be
associated consistently with CFS. This led us to hypothesize that sleep homeostasis, rather than
sleep architecture, may be perturbed in CFS. To probe this hypothesis, we measured and
compared EEG frequencies associated with restorative sleep between persons with CFS and
matched controls, both derived from a population-based sample.
Methods: We evaluated overnight polysomnography (PSG) in 35 CFS and 40 control subjects.
PSG records were manually scored and epochs containing artifact removed. Fast Fourier
Transformation was utilized to deconstruct individual EEG signals into primary frequency bands of
alpha, delta, theta, sigma, and beta frequency domains. The spectral power of each frequency
domain for each sleep state was compared between persons with CFS and matched controls.
Results: In persons with CFS, delta power was diminished during slow wave sleep, but elevated
during both stage 1 and REM. Alpha power was reduced during stage 2, slow wave, and REM sleep.
Those with CFS also had significantly lower theta, sigma, and beta spectral power during stage 2,
Slow Wave Sleep, and REM.
Discussion: Employing quantitative EEG analysis we demonstrate reduced spectral power of
cortical delta activity during SWS. We also establish reduced spectral power of cortical alpha
activity, with the greatest reduction occurring during REM sleep. Reductions in theta, beta, and
sigma spectral power were also apparent.
Conclusion: Unremitting fatigue and unrefreshing sleep, the waking manifestations of CFS, may be
the consequence of impaired sleep homeostasis rather than a primary sleep disorder.
Background
Chronic fatigue syndrome presents clinically as incapaci-
tating physical and mental fatigue, frequently accompa-
nied by unrefreshing sleep, impaired memory and
concentration, and diffuse musculoskeletal pain [1]. An
absence of characteristic clinical signs or diagnostic labo-
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ratory abnormalities further create a diagnostic challenge
[1]. Adding to this complexity, the clinical picture of CFS
is similar to that observed with sleep disorders [2].
Symptoms of CFS have been attributed to sleep disorders
such as alpha-delta sleep [3], upper airway resistance syn-
drome [4], obstructive sleep apnea syndrome [5] and
insomnia [6]. However, sleep disorders within CFS may
also represent non-specific findings attributable to comor-
bid disease or ascertainment bias [7]. To assess the rela-
tionship between sleep disorders with symptoms of CFS,
and avoid potential confounds associated with studying
clinic-based patients, we recruited persons with CFS who
were identified during the Centers for Disease Control
and Prevention's CFS population surveillance of Wichita,
Kansas [8]. During a 2-day in-hospital research study we
evaluated nocturnal sleep characteristics with polysom-
nography (PSG) and daytime sleepiness with multiple
sleep latency testing (MSLT) and questionnaires.
Our polysomnographic assessment of nocturnal sleep
architecture, MSLT, and Epworth Sleepiness scores dem-
onstrated no difference in sleep architecture or propensity
for daytime sleepiness between community-based indi-
viduals with CFS and their matched controls [9,10]. This
absence of overt sleep pathology and daytime sleepiness
led us to concur with Mahold [7] and others [11] who sus-
pect that unremitting fatigue and unrefreshing sleep, hall-
mark traits of CFS, do not reflect a primary sleep disorder.
Rather, these symptoms may reflect perturbed sleep
homeostasis [12]. To assess the biological plausibility of
this hypothesis, we assessed EEG frequencies associated
with restorative sleep in persons with CFS and compared
them with their matched non-fatigued controls.
Methods
This study received Institutional Review Board approval
from the Centers for Disease Control and Prevention
(CDC) and collaborating institutions. Administration of
protocols adhered to U.S. Department of Health and
Human Services human experimentation guidelines. All
participants were over 21 years of age and provided writ-
ten informed consent.
Study population
The present study, conducted between January and July of
2003, evaluated participants with CFS and healthy con-
trols followed from 1997 through 2000 in the Wichita
CFS Surveillance Study [8]. The Wichita CFS Surveillance
Study employed a random digit-dialing telephone survey
to screen 56,146 adult residents, 18 to 69 years of age, liv-
ing in Wichita in 1997. That survey identified 5,295 per-
sons with fatigue persisting one month's duration or
longer. Those individuals were asked to participate in a
detailed telephone interview; 3,528 agreed to participate,
along with a subset of 3,634 randomly selected non-
fatigued (NF) controls. The detailed interview was used to
identify cases with fatigue of 6 months duration or longer,
who did not feel better after rest, who did not report any
fatigue-associated medical or psychiatric conditions, and
who reported at least four of the eight CFS case-defining
symptoms (CFS-like cases) [1]. CFS-like cases were invited
to participate in a clinical examination to confirm CFS by
1994 criteria [1]. Two Randomly selected NF controls
matched to CFS-like cases based on age, sex, race, and
body mass index were also asked to participate in the clin-
ical evaluation. We followed this telephone interview
cohort in 1998, 1999, and 2000 with telephone inter-
views and clinical evaluations.
In-hospital study participants
In 2002, all subjects ever having met criteria for clinically
confirmed CFS during the surveillance study were invited
to participate in the current study. Thus, we invited the 70
people, who were classified as having CFS at least once
during the 4-year surveillance study, to participate in the
current study and 58 (83%) agreed. We randomly selected
an equal number of surveillance participants who had
unexplained fatigue for at least six months or longer, at
least once during the 4-year surveillance study, but who
did not meet full CFS criteria, and 59 (84%) were
enrolled. Finally, we enrolled 60 non-fatigued control
subjects who had participated in the same surveillance
program, but did not exhibit any medical or psychiatric
exclusion, and had never reported fatigue of at least 1-
month duration. They were matched to CFS cases based
on sex, age, race, and body mass index.
Clinical evaluation
All subjects were admitted to a Wichita hospital research
unit for 2 days. On admission, subjects underwent reeval-
uation in terms of current CFS symptoms and exclusion-
ary conditions. At the hospital, 43 current CFS cases were
confirmed. These consisted of past CFS cases that still had
CFS, as well as new onset CFS cases derived from chroni-
cally fatigued persons who previously did not meet CFS
criteria. Persons with insufficient symptoms of fatigue to
be considered CFS, at the time of the in hospital study,
were not included in this report. Because NF controls were
individually matched to cases with a CFS diagnosis during
the prior surveillance study, and this in-hospital study
occurred two years later, and subjects were classified
according to current diagnostic status, individual match-
ing could not be maintained. However, the groups were
demographically comparable. The mean age of the sam-
ple was 50.5 years and mean body mass index was 29.2.
Classification
Participants were admitted to a Wichita hospital research
unit for 2 days where they underwent a standardizedBehavioral and Brain Functions 2009, 5:43 http://www.behavioralandbrainfunctions.com/content/5/1/43
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review of past medical history, a standardized physical
examination, and provided blood and urine for routine
analysis [1,8]. To identify psychiatric conditions exclu-
sionary for CFS, specifically trained and licensed psychiat-
ric interviewers administered the Diagnostic Interview
Schedule for current Axis I disorders. Subjects with no
exclusionary conditions were considered to be CFS if they
met criteria of the 1994 CFS case definition [1], as applied
following recommendations of the International Chronic
Fatigue Syndrome Study Group [8]. Subjects completed a
series of rating scales to assess functional impairment (SF-
36), fatigue severity (MFI), and occurrence, frequency and
severity of the 8 CFS defining symptoms [13]. Classifica-
tion as a current CFS case was based on cutoff scores in
these rating scales with respect to the 3 dimensions of CFS
specified in the case definition, i.e., impairment, fatigue,
and accompanying symptoms [13]. Subjects meeting
these criteria at the time of the study were classified as hav-
ing CFS (n = 35) and those who met no criteria were clas-
sified as well (n = 40).
Polysomnographic and Multiple Sleep Latency Techniques
Detailed descriptions of data collection techniques and
protocols for nocturnal PSG and daytime multiple sleep
latency testing (MSLT) have been described elsewhere
[9,10]. Briefly, all PSG procedures were conducted within
a 4-bed laboratory established at Wesley Medical Center,
Wichita, KS. Each subject had a standard nocturnal PSG
performed on the first night in the Medical Center, fol-
lowed by MSLT the next day and a second PSG performed
on the second night. Subjects were asked to arrive three
hours before their typical bedtime on Night 1 to allow
adequate time for electrode application and standard bio-
calibrations. Lights out and lights on times were standard-
ized at 22:00 and 07:00, respectively, for all subjects.
During the PSG, standard gold cup electrodes were
employed for the recording of electroencephalography
(EEG), electroencephalography (EOG), and electromyog-
raphy (EMG) in the following montage: central EEGs (C3-
A2//C4-A1), occipital EEGs (O1-A1//O2-A2) EEGs, left
and right monopolar EOGs, surface mentalis EMGs, and a
three lead electrocardiogram. These signals were collected
at a sampling rate of 200 Hz. Respiration was measured
with inductance plethysmography-like belts placed
around the chest and abdomen. A nasal cannula, attached
to a pressure transducer, was positioned in close approxi-
mation to the nares to provide indices of airflow. A pulse
oximeter probe, to measure hemoglobin oxygen satura-
tion (Sp02), was applied to either the right or left index
finger. Leg movement activity was measured via surface
EMG electrodes applied to both the right and left anterior
tibialis muscles.
Scoring of polysomnography data
All PSG data was scored by a single registered polysom-
nology technologist who was blinded to each subjects'
enrollment classification. Each PSG recording was manu-
ally scored in 30 second epochs, with each epoch scored
as either wake, Stages 1, 2, slow wave, or rapid eye move-
ment (REM) sleep. Criteria for scoring sleep and respira-
tory variables were upon based definitions used by the
Sleep Heart Health Study [14].
Fast Fourier Transformation of EEG Data
Following manual scoring of each subject's night one and
two PSG recordings, the night two PSG was prepared for
spectral analyses. Each 30-second epoch was assessed for
the presence of EEG artifact (random high frequency
noise attributed to movement arousal, etc), which was
marked as movement artifact and excluded from further
analysis. Removing entire epochs insured that the final
FFT data output would be appropriately synchronized
with each scored, artifact free, PSG epoch.
Following identification of all epochs containing artifact,
we utilized the FFT algorithm within Somnologica Science
(Embla, Denver Co., USA) to determine the spectral anal-
ysis profile of the EEG signal obtained between electrodes
placed at the C3-A2 region of the scalp. The FFT algorithm
was adjusted to deconstruct the EEG signal into the pri-
mary frequency domains described in Table 1 (Table 1).
Since EEG signals were recorded at 200 Hz, each thirty sec-
ond epoch contained 6,000 EEG data points per channel.
The FFT analysis window processed 256 samples of EEG
data as a signal unit, with each "unit" representing 1.28
seconds of EEG data. As the FFT analysis window pro-
gressed along the EEG signal, the final 128 data points
within the preceding analysis window were included with
the next 128 EEG data points, to be analyzed. This analy-
sis routine produced 23.44 discrete FFT values for each 30
second epoch of EEG data. These 23.44 FFT values were
Table 1: primary EEG frequencies
Frequency name Frequency range
(Hertz)
Delta 0.5 - 3.99
Theta 4.0 - 7.99
Alpha 8.0 - 11.99
Sigma 12.0 - 13.99
Beta 14.0 - 24.99Behavioral and Brain Functions 2009, 5:43 http://www.behavioralandbrainfunctions.com/content/5/1/43
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then averaged into one FFT value representing the entire
30 second epoch. This methodological approach enabled
us to define both the "power" within the alpha, delta,
theta, beta and sigma frequency bands (Table 1) as well as
the relative contribution that the power within each fre-
quency provided to the overall power of the EEG signal.
Medication use
Clinic staff reviewed all current medications (prescription
and over the counter) that study participants were taking.
All participants continued their medication use through-
out the study. CDC CFS research program staff classified
these medications as those affecting sleep (i.e., inducing
sleep, inhibiting sleep or with mixed effects) or not affect-
ing sleep. Medications that we encountered during this
study included analgesics (e.g., hydrocodone, Lortab, oxy-
codone, Propoxyphene), antidepressants (e.g., Celexa™,
amitriptyline, imipramine, Lexapro™, Wellbutrin™,
Effexor, Prozac™, Zoloft™, Paxil™, fluoxetine), antianxiety
(Alprazolam), antihistamines (e.g., diphenhydramine,
chlorpheneramine, benadryl, promethazine), decongest-
ants (e.g., pseudoephedrine, guaifenesen), anticonvul-
sants (e.g., Topamax, Neurotin, clonazepam), anti-sleep
phase disorder (melatonin), blood pressure controlling
(e.g., Clonidine, Proamatine), antipsychotics (e.g., Sero-
quel, Zyprexa, Fluvoxamine), stimulants (e.g., methylphe-
nidate, Provigil), peristaltic stimulants
(Metoclopramide), and muscle relaxants (cyclobenz-
aprine). Medications affecting sleep were handled as a
binary measure (i.e., they used or did not use one or more
of those named above). Analyses took into account use of
sleep affecting medications.
Statistical analysis
Spectral power for each frequency domain was deter-
mined for each 30 second epoch of sleep as well as wake-
fulness prior to sleep onset. Independent samples t-tests
were employed to assess values of alpha, delta, theta, beta
and sigma between control subjects with CFS subjects.
Group differences were considered significant at a two-
tailed significance of 0.05.
Results
Seventy five of the 177 study participants met criteria as
either CFS (n = 35) or NF control (n = 40). Remaining par-
ticipants were excluded on the basis of significant medical
or psychiatric exclusionary criteria that emerged during
clinical evaluation, or else symptoms were insufficient to
be classified as CFS. Table 2 (Table 2) provides demo-
graphics comparing non-fatigued males with CFS males
and non-fatigued females with CFS females. Most partici-
pants were white women and no important differences
existed between values of age or body mass index.
Values of sleep architecture measured during overnight
PSG did not differ between NF controls and those with
Table 2: demographics
Males CFS
(n = 5)
Control NF
(n = 4)
Two-tailed significance
BMI 28.2
(5.4)
29.5
(5.7)
P = 0.740
Age 47.0
(0.7)
48.0
(10.9)
P = 0.841
Race White = 5 White = 4
Females CFS
(n = 30)
Control NF
(n = 36)
Two-tailed significance
BMI 28.8
(4.1)
29.4
(8.1)
P = 0.715
Age 50.9
(9.1)
50.8
(8.1)
P = 0.988
Race White = 27
AmIndian = 1
Multiracial = 1
Black = 1
White = 36
Data presented as the mean ± 1 standard deviation of the meanBehavioral and Brain Functions 2009, 5:43 http://www.behavioralandbrainfunctions.com/content/5/1/43
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CFS, and those findings have been published previously
[10]. Measures of physiologic sleepiness, as determined
by the MSLT, also did not differ between groups [9]. In
addition, medication use was similar between NF controls
and those with CFS. Subjects who reported using any of
the aforementioned medications routinely demonstrated
experienced increased REM latencies (P = 0.02) and/or an
increased percentage of Stage 1 sleep (P = 0.01). However,
REM latency and percentage of Stage 1 sleep did not differ
between the NF control group and CFS group [10].
PSG records from the 35 people with CFS and 40 non-
fatigued controls were analyzed with the FFT algorithm.
Table 3 illustrates that spectral power of cortical alpha
activity was significantly reduced in CFS subjects during
Stage 2 Sleep, Slow Wave Sleep (SWS), and REM (Table 3).
Table 4 denotes that spectral power of cortical delta activ-
ity was also significantly reduced in SWS but increased in
both Stage 1 sleep and REM (Table 4). Similarly, Table 5
demonstrates that spectral power of cortical theta activity
was significantly reduced in Stage 1, 2, and Slow Wave
Sleep (Table 5). Finally, Table 6 illustrates that spectral
power of cortical sigma activity was significantly reduced
in Stage 2, SWS, and REM (Table 6) while spectral power
of cortical beta activity was significantly reduced in Stage
2 Sleep, Slow Wave Sleep (SWS), and REM (Table 7).
Discussion
We sought to determine whether the power spectra of EEG
frequencies associated with restorative sleep differed
between persons with CFS and matched controls.
Employing quantitative EEG analysis we demonstrate
reduced spectral power of cortical delta activity during
SWS. We also establish reduced spectral power of cortical
alpha activity, with the greatest reduction occurring dur-
ing REM sleep. Reductions in theta, beta, and sigma spec-
tral power were also apparent. In contrast, the percentage
of PSG recording time spent awake, in light sleep, slow
wave and REM sleep, as well as daytime propensity for
sleepiness, did not differ between persons with CFS and
their matched controls [9,10].
Alpha activity is the primary EEG frequency associated
with wakefulness and vigilance [15-17]; alpha activity
increases following administration of wake promoting
drugs [18] and is attenuated during cortical quiescence
[19,20]. Delta activity is the primary EEG frequency asso-
ciated with slow wave sleep (21). Increased delta spectral
power occurs immediately following sleep restriction or
deprivation, and is postulated to reflect a homeostatic
sleep rebound. Attenuation of delta power is associated
with impaired sleep homeostasis [21].
Experimentally reduced delta spectral is followed by
increased perception of pain, generalized discomfort and
fatigue [22,23]. Key executive functions such as memory
consolidation also are negatively impacted [24,25]. Meta-
bolic dysfunctions emerge as decreased insulin sensitivity,
inadequate increase in subsequent insulin release, and
reduced glucose tolerance [26]. Sympathovagal imbal-
ance arises and sympathetic tone dominates, as deter-
mined by diminished heart rate variability [26]. These
Table 4: delta power
Stage 1 Stage 2 Slow Wave Sleep REM
CFS (n = 35) 4.87E-9 ± 7.16E-11 1.17E-08 ± 5.26E-11 3.48E-08 ± 2.29E-10 3.76E-09 ± 2.73E-11
Control NF (n = 40) 4.22E-9 ± 5.86E-11 1.16E-08 ± 8.02E-11 3.83E-08 ± 2.36E-10 3.54E-09 ± 5.35E-11
Two Tailed
Significance
P < 0.0001 P = 0.323 P < 0.0001 P < 0.0001
Data presented as the mean ± 1 standard error of the mean
Table 3: alpha power
Stage 1 Stage 2 Slow Wave Sleep REM
CFS (n = 35) 1.17E-09 ± 1.45E-11 1.42E-09 ± 6.59E-12 1.525-09 ± 1.44E-11 6.84E-10 ± 5.95E-12
Control NF (n = 40) 1.22E-09 ± 1.86E-11 1.73E-9 ± 1.01E-11 2.07E-09 ± 2.43E-11 8.76E-10 ± 9.50E-12
Two Tailed
Significance
P = 0.058 P < 0.0001 P < 0.0001 P < 0.0001
Data presented as the mean ± 1 standard error of the meanBehavioral and Brain Functions 2009, 5:43 http://www.behavioralandbrainfunctions.com/content/5/1/43
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sensory, cognitive, metabolic and sympathovagal dys-
functions are alleviated when delta spectral power is per-
mitted to return to baseline levels [26].
We speculate that reduced spectral power of cortical delta
and alpha activity observed in CFS signify impaired sleep
homeostasis. The co-occurrence of fatigue, generalized
pain, discomfort, impaired memory, and insulin resist-
ance observed between persons with CFS and healthy con-
trol subjects with experimentally attenuated delta power
is striking. Yet, the 10% reduction of delta spectral power
within those with CFS may be considered modest in com-
parison with the 50-70% reductions employed to elicit
sensory and physiologic responses within healthy subjects
[26]. This compels us to postulate that the cumulative
effects of chronic, but modest, attenuations of delta spec-
tral power evokes outcomes similar to those appearing
after a brief, but significant suppression.
Data presented here converge with that from another
recent study demonstrating reduced spectral power of
delta EEG activity within CFS subjects following sleep
restriction [12]. Yet, results from our convergent studies
diverge from that of an earlier study demonstrating
increased alpha activity in CFS, particularly during SWS
[2]. In that study, CFS subjects were recruited from a
clinic-based program, which raised their likelihood of co-
morbid medical conditions and subsequent biasing of
results. The small sample size and qualitative approach
for measuring and quantifying alpha activity employed in
that study may also have contributed to these paradoxical
findings.
Our observations corroborate those of Mahold [7] who
proposed that unremitting fatigue and unrefreshing sleep,
hallmark traits of CFS, do not reflect the presence of a pri-
mary sleep disorder. Our findings also confirm and
extend recent observations of Armitage [12] who pro-
posed that impaired sleep homeostasis contributes to the
signs and symptoms of CFS. Nonetheless, a plausible
alternate hypothesis is that sympathovagal imbalance
may account for our findings as well as key signs and
symptoms of CFS [27-29].
Sympathovagal imbalance with sympathetic predomi-
nance, expressed as reduced heart rate variability, existed
in those CFS subjects studied here [30]. Increased sympa-
thetic tone is associated with reduced spectral power of
alpha activity during wakefulness [31,32]. However, it
remains uncertain whether increased sympathetic tone
also suppresses delta spectral power during sleep. Thus,
attenuated delta power resulting from impaired sleep
homeostasis, rather than a primary disorder of sym-
pathovagal imbalance, remains the more parsimonious
hypothesis to guide future studies eliciting mechanisms
contributing to our findings.
Limitations
Interactions between both psychotropic and non psycho-
tropic medications with central nervous system activity
are complex and extensive. Thus, it is feasible to consider
that medication use may have potentially contributed to
our findings. However, the risk for adverse effects associ-
ated with abrupt withdrawal of prescribed medications
contributed to our a-prior decision to avoid restricting
Table 6: sigma power
Stage 1 Stage 2 Slow Wave Sleep REM
CFS (n = 35) 2.98E-10 ± 3.77E-12 4.86E-10 ± 2.41E-12 3.65E-10 ± 2.51E-12 1.51E-10 ± 1.38E-12
Control NF (n = 40) 2.91E-10 ± 3.59E-12 5.42E-10 ± 2.56E-12 4.22E-10 ± 3.10E-12 1.82E-10 ± 1.61E-12
Two Tailed
Significance
P = 0.180 P < 0.0001 P < 0.0001 P < 0.0001
Data presented as the mean ± 1 standard error of the mean
Table 5: theta power
Stage 1 Stage 2 Slow Wave Sleep REM
CFS (n = 35) 1.57E-9 ± 1.65E-11 2.35E-09 ± 8.98E-12 3.52E-09 ± 1.89E-11 1.36E-09 ± 8.53E-12
Control NF (n = 40) 1.40E-09 ± 1.26E-11 2.41E-09 ± 7.78E-12 3.75E-09 ± 1.61E-11 1.37E-09 ± 8.71E-12
Two Tailed
Significance
P < 0.0001 P < 0.0001 P < 0.0001 P = 0.228
Data presented as the mean ± 1 standard error of the meanBehavioral and Brain Functions 2009, 5:43 http://www.behavioralandbrainfunctions.com/content/5/1/43
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medication use prior to PSG. Future studies will be neces-
sary to determine whether medications routinely pre-
scribed to counter symptoms of CFS are associated with
attenuated alpha and delta spectral power.
Perturbations of EEG spectral power also correspond with
neurodegenerative disease [33], acute depression [34],
emotional stress [35], diabetes [36], and medication [37].
To, reduce the likelihood of this, all study participants
underwent full clinical evaluations to insure the absence
that psychiatric or medical disorders, or medication
effects, that could potentially confound our results. Thus,
we are confident that the attenuation in the spectral power
of delta and alpha activity observed in CFS is not attrib-
uted to psychiatric or medical pathology nor represent the
effect of pharmaceuticals.
Other limitations also reflect aspects of study design. Our
participants represented a population based sample, min-
imizing recruitment bias. However, those with CFS had
been ill for more than 5-years, so survival bias must be
considered. Participants on the whole were overweight or
obese, so the results cannot be generalized to those of nor-
mal BMI. Obesity is also associated with stimulation of
several important inflammatory pathways. This was con-
trolled for by the matched case control design and statisti-
cal analysis, but future studies should be designed to
evaluation inflammatory markers in some detail. Addi-
tionally, most participants were older women and this
study did not include data on menopausal status, which
has an important impact on sleep. Our matched case-con-
trol study design and statistical analyses largely corrected
for effect of menopausal status on the results. However, as
with the other limitations discussed above, further studies
evaluating the effect of menopausal status must be con-
ducted to explore this.
Conclusion
We appreciate that data derived through our experimental
paradigm cannot confirm the hypothesis that impaired
sleep homeostasis and increased cortical quiescence exist
within CFS. Future studies using methods known to aug-
ment delta and alpha spectral power, such as meditation
[38], graded exercise [39] or administration of gamma
hydroxybutyrate [40], followed by assessment of EEG
spectral power and symptom expression are required to
address this. Outcomes from those studies will not only
provide new insight into potential mechanisms contribut-
ing to the signs and symptoms of CFS, but also potentially
define new therapeutic interventions to restore sleep
homeostasis in select patient populations.
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